T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2027-05-29
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well T-DMI with or without abemaciclib works for the
treatment of HER2-positive breast cancer that has spread to other places in the body
(metastatic). T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy
drug called DM1. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and
delivers DM1 to kill them. Abemaciclib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Giving T-DM1 and abemaciclib may work better in treating
patients with breast cancer compared to T-DM1 alone.